$IVHI
Invech Holdings, Inc.

2024 Q3 Form 10-Q Financial Statement

#000168316824005462 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.16K $29.62K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.647K $16.16K $29.62K
YoY Change -8.74% 3087.18%
Operating Profit -$5.647K -$16.16K
YoY Change -8.74% 3087.18%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.16K -$29.62K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$5.647K -$16.16K -$29.62K
YoY Change -8.74% 3087.18% 30.25%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 10.52M shares 10.52M shares
Diluted Shares Outstanding 10.52M shares 10.52M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change
Cash & Equivalents $0.00 $0.00 $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $3.150K
Receivables
Other Receivables
Total Short-Term Assets $0.00 $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $0.00 $0.00
Total Long-Term Assets $0.00 $0.00
Total Assets $3.150K $0.00 $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $5.391K $5.391K $5.390K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $79.25K $63.09K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $79.25K $63.09K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $88.05K $79.25K $63.09K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$298.0K -$292.4K
YoY Change
Common Stock $10.52K $10.52K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$84.90K -$79.25K -$63.09K
YoY Change
Total Liabilities & Shareholders Equity $3.150K $0.00 $0.00
YoY Change

Cashflow Statement

Concept 2024 Q3 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$5.647K -$16.16K -$29.62K
YoY Change -8.74% 3087.18% 30.25%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$16.16K -$29.62K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.16K 22.62K
YoY Change
NET CHANGE
Cash From Operating Activities -16.16K -29.62K
Cash From Investing Activities
Cash From Financing Activities 16.16K 22.62K
Net Change In Cash 0.000 -7.000K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$16.16K -$29.62K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Assets
Assets
0 usd
CY2023Q4 us-gaap Assets
Assets
7000 usd
CY2024Q2 IVHI Due To Related Party
DueToRelatedParty
69417 usd
CY2023Q4 IVHI Due To Related Party
DueToRelatedParty
30641 usd
CY2024Q2 IVHI Due To Former Related Party
DueToFormerRelatedParty
4443 usd
CY2023Q4 IVHI Due To Former Related Party
DueToFormerRelatedParty
4443 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5391 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5391 usd
CY2024Q2 us-gaap Liabilities
Liabilities
79251 usd
CY2023Q4 us-gaap Liabilities
Liabilities
40475 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
10521 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10521 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202294 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202294 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292366 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246590 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-79251 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-33475 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16159 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
507 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45776 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23246 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
16159 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
507 usd
us-gaap Operating Expenses
OperatingExpenses
45776 usd
us-gaap Operating Expenses
OperatingExpenses
23246 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16159 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-507 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-45776 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23246 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16159 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-507 usd
us-gaap Net Income Loss
NetIncomeLoss
-45776 usd
us-gaap Net Income Loss
NetIncomeLoss
-23246 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10521335 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10521335 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9521335 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9521335 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10521335 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10521335 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9521335 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9521335 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-33475 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-29617 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-63092 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-16159 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-79251 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-9834 usd
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
-0 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22739 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7427 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-507 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6920 usd
us-gaap Net Income Loss
NetIncomeLoss
-45776 usd
us-gaap Net Income Loss
NetIncomeLoss
-23246 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45776 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23246 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
38776 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
23246 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
40000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38776 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63246 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
40000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_z3ehyRyvdyD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zVnfcL3bPyB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">Concentration of credit risk</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments which potentially subject the Company to concentration of credit risk consist of cash deposits and customer receivables. The Company maintains cash with various major financial institutions. The Company performs periodic evaluations of the relative credit standing of these institutions. To reduce risk, the Company performs credit evaluations of its customers and maintains reserves when necessary for potential credit losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Each share of Convertible Series A Preferred Stock is convertible into 1,000 shares of common stock. In addition, the Convertible Series A Preferred Stock has voting privileges of 1,000 votes per one share of Series A. The Convertible Series A Preferred Stock is not entitled to dividend.
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
30641 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
38776 usd
CY2023Q4 us-gaap Cash
Cash
7000 usd
CY2023Q4 us-gaap Assets
Assets
7000 usd
CY2023Q4 IVHI Due To Related Party
DueToRelatedParty
30641 usd
CY2023Q4 IVHI Due To Former Related Party
DueToFormerRelatedParty
4443 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5391 usd
CY2023Q4 us-gaap Liabilities
Liabilities
40475 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10521 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202294 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246590 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-33475 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-005462-index-headers.html Edgar Link pending
0001683168-24-005462-index.html Edgar Link pending
0001683168-24-005462.txt Edgar Link pending
0001683168-24-005462-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
invech_ex3101.htm Edgar Link pending
invech_ex3102.htm Edgar Link pending
invech_ex3201.htm Edgar Link pending
invech_ex3202.htm Edgar Link pending
invech_i10q-063024.htm Edgar Link pending
ivhi-20240630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ivhi-20240630_cal.xml Edgar Link unprocessable
ivhi-20240630_def.xml Edgar Link unprocessable
ivhi-20240630_lab.xml Edgar Link unprocessable
invech_i10q-063024_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ivhi-20240630_pre.xml Edgar Link unprocessable